OHSU in the news

Why don't doctors feel like heroes anymore?

Medscape November 21, 2023
In a story exploring they myth of the health care hero, Brian Park, M.D., discusses how that label was problematic and challenging for many health care workers as they experienced the highs and lows of the pandemic. “I think a lot of people feel ashamed that they feel burnout, because they’re supposed to be heroes, putting on their capes and masks. They’re waking up and saying, ‘I’m exhausted and I can’t play that part today. But I know that’s the societal expectation of me,’” he says.

OHSU urges health precautions amid virus ‘triple threat’ over holidays

KOIN-TV November 20, 2023
To prevent becoming sick while visiting with family and friends during the winter holiday season, William Messer, M.D., Ph.D., offers tips such as frequent hand washing, covering coughs and sneezes, and keeping hands off of eyes, mouths and noses, noting “those are where mucus membranes that are most susceptible to infection.”

OHSU TikTok study finds teens lack understanding of period health

KOIN-TV November 20, 2023
A study by Maureen Baldwin, M.D., found U.S. young adult TikTok users have significant misconceptions about the safety of period management options. Baldwin says: “Due to insufficient menstrual health education at school, these conversations are often left to families and friends, who may be perpetuate myths rooted in religious or cultural norms and biases. This can create a dangerous cycle of misinformation.”

Smartphone app helps TAVR patients avoid major complications

Cardiovascular Business November 20, 2023
Research by Julie Doberne, M.D., Ph.D., finds smartphone-based digital health applications help transcatheter aortic valve replacement patients achieve better outcomes 90 days after undergoing a replacement procedure.

‘This gives us more leeway’: Intravenous secukinumab effective in axial spondyloarthritis

Healio Rheumatology November 20, 2023
Atul Deodhar, M.D., tells Healio Rheumatology that a study found an intravenous form of the axial spondylarthritis therapy secukinumab met all primary efficacy endpoints and was safe, adding: “We thought that the option of an IV preparation of secukinumab would offer flexibility in treatment decisions made by patients and providers, especially in the United States, considering the medical insurance landscape.”
See more stories